Screener
Tarsus Pharmaceuticals, Inc. TARS Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling and marketing | 90,002 | 65,857 | 174,484 | 126,143 |
| General and administrative | 60,695 | 37,156 | 112,642 | 61,865 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations | (19,908) | (22,184) | (26,030) | (48,464) |
| Other reconciling items(1) | 1,357 | 1,844 | 512 | 3,004 |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s business segments — SG&A?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — SG&A of $60.7M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — SG&A changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — SG&A increased by 63.4% year-over-year, from $37.16M to $60.7M.
- What does business segments — SG&A mean?
- Encompasses the overhead costs required to support the business segment's operations, including personnel, legal, and corporate infrastructure. It serves as a measure of the company's operational leverage and administrative efficiency.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude